

Date 15 May 2023

Acquisition of assets in relation to ordinary shares of Grace Water Med Company Limited Re:

To Director and manager, The Stock Exchange of Thailand

JSP Pharmaceutical Manufacturing (Thailand) PCL. ("the Company") would like to inform the resolution of the Board of Directors meeting no. 5/2023 on 12 May 2023, which significant resolution was approval of assets acquisition in relation to 21,118 ordinary shares of Grace Water Med Company Limited ("GWM"), accounted for 52.8 of registered and paid-up capital of GWM, with consideration approximately THB 43.9 million. Therefore, GWM becomes the Company's subsidiary with details as follow:

1. Date of transaction

15 May 2023

2. Counterparties

Buyer: JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd.

Seller: NCL International Logistics Public Company Limited ("NCL")

The Buyer and the Seller are not connected persons under the Rules on Connected Transactions

3. General characteristics and transaction size

On 12 May 2023, the Board of Directors' Meeting no. 5/2023 had a resolution to approve the Company to invest in 21,118 ordinary shares of Grace Water Med Company Limited, accounted for 52.8% of registered and paid-up capital of GWM, held by NCL with consideration of THB 43.9 million approximately. Therefore, GWM becomes the Company's subsidiary.

the Company used financial information presented in the Company's interim financial information as of 31 March 2023. The highest transaction size was 3.4% based on total value of consideration. In connection with acquisition of assets in the last six months, the highest transaction size was 11.2% based on total value of consideration. In conclusion, this transaction is not required to execute under the Notification of the Capital Market Supervisory Board No. Tor Chor 20/2551 (2008) and is not a connected transaction. The details of computation are presented in the next page.



			Transaction	
			size in the	Total
	Calculation method	Transaction	past	transaction
Basis	(Unit: Thousand Baht)	size	six months	size
1. Net tangible	Shareholding interest $\times$ NTA of investeee $\times$ 100	2.4	7.8	10.2
assets	NTA of Listed Company	2.4	7.0	10.2
2. Net operating	Shareholding interest × Net profit of investee	Not available since the Company had net		
profit	$\sim$ Net profit of listed company $\times$ 100	loss in the last 12 months		
3. Total value of	Total value of consideration $\times 100$	3.4	7.8	11.2
consideration	$\overline{Total\ assets\ of\ listed\ company}}^{\times\ 100}$	3.4	7.0	11.2
4. Value of	Numbe of shares issued by mean of consideration	Not available since there is no issuance of		
securities issued	Number of issued and paid — up shares of listed company	shares.		
as consideration	× 100			

## 4. Details of acquired assets

GWM had summary details of the business as below:

Company name	Grace Water Med Company Limited			
Business description	Manufacturing and distributing hemodialysis water and distributing of medical			
	products			
Office address	13/7 Moo 8 Bang Muang-Bang Ku Lat Rd., Bang Muang Sub-District, Bang Yai			
	District, Nonthaburi			
Registered date	3 August 2016			
Registered and paid-up capital	THB 40,000,000			
Number of shares	40,000 shares			
Par value	THB 1,000.00 per share			

Shareholder structure pre and post transaction will be as follow:

		Pre-transaction		Post-transaction	
		Number of		Number of	
No.	Name of shareholders	shares (Shares)	%	shares (Shares)	%
1	Mr. Thongchai Pami	3,327	8.3	3,327	8.3
2	Mrs. Phornnapha Prasertpakdeekul	1,111	2.8	1,111	2.8
3	Ms. Chidchanok Chaitad	1,926	4.8	1,926	4.8
4	Mrs. Chonlada Marutwong	3,926	9.8	3,926	9.8
5	Mrs. Supaphorn Yudaeng	1,111	2.8	1,111	2.8
6	Mr. Wisit Prasitsirikul	7,481	18.7	7,481	18.7
7	NCL International Logistics Public Company Limited	21,118	52.8	-	-
8	JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd.	-	-	21,118	52.8
	Total	40,000	100.0	40,000	100.0



## 5. Total consideration and basis of determination

The Company will pay consideration amounting to THB 43.9 million to the Seller via cash. The Consideration is mutually agreed between the Buyer and the Seller. The Company's management considers reasonableness of transaction price by a ratio of price to earnings with reference to similar businesses operate in the same industry with GWM.

## 6. Expected benefits to the Company

GWM has business plan to expand production factory in order to increase production capacity with additional capital expenditures. With reference to GWM's current business value, GWM's business value should increase by 3 - 4 times after the expansion completed. In addition, the Company will have benefits from expanding customers base in dietary supplements and personalised medicine for non-communicable diseases (NCDs), which tend to increase over time.

## 7. Source of fund

The Company will use working capital to fulfill this transaction. The use of such working capital will not affect the operations of the Company nor the capability to pay dividends to the shareholders

Please be informed accordingly.

Sincerely yours,

JSP Pharmaceutical Manufacturing (Thailand) PCL.

Investor Relations

Tel. 064 479 1691

Email ir@jsppharma.com

Ms. Jirada Daengprasert

Company Secretary